van Vollenhoven, Ronald
Strand, Vibeke
Takeuchi, Tsutomu
Chávez, Nilmo
Walter, Pablo Mannucci
Singhal, Atul
Swierkot, Jerzy
Khan, Nasser
Bu, Xianwei
Li, Yihan
Penn, Sara K.
Camp, Heidi S.
Aelion, Jacob
Funding for this research was provided by:
AbbVie
Article History
Received: 7 February 2024
Accepted: 30 June 2024
First Online: 29 July 2024
Declarations
:
: Studies were conducted per the International Conference on Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. Study-related documents were approved by independent ethics committees and institutional review boards. All patients provided written, informed consent.
: Not applicable.
: AbbVie Inc. was the trial sponsor, and the trial was designed by AbbVie Inc., the authors, and investigators. Clinical data were collected by the investigators, their teams, and AbbVie Inc. AbbVie Inc. was involved in data analysis, the interpretation of results and the preparation, review and approval of the final version of this report. All the authors had access to the data, reviewed and approved the final version, made the decision to submit the manuscript for publication, and attest to the accuracy and completeness of the data. The corresponding author had access to all relevant data and the final responsibility to submit for publication. A medical writer, employed by AbbVie Inc., assisted with preparing an initial draft under the direction of the authors.
: Some of the results reported in this manuscript were originally presented at the American College of Rheumatology 2023 Congress, as follows: van Vollenhoven R et al., Upadacitinib Monotherapy versus Methotrexate in Patients with Rheumatoid Arthritis: Efficacy and Safety Through 5 Years in the SELECT-EARLY Randomized Controlled Trial. <i>Arthritis Rheumatol</i>. 2023; 75 (suppl 9); .
: R van Vollenhoven: Research Support (institutional grants): BMS, UCB; support for educational programs (institutional grants): AstraZeneca, Galapagos, MSD, Novartis, Pfizer, Roche, Sanofi, UCB; consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, BMS, Galapagos, Janssen, Pfizer, RemeGen, UCB; speaker, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, BMS, Galapagos, GSK, Janssen, Pfizer, UCB.V Strand: Consultant for AbbVie, Alpine Immune Sciences, Alumis, Amgen, AstraZeneca, Bayer, Blackrock, BMS, Boehringer Ingelheim, Celltrion, Ermium, Genentech/Roche, GlaxoSmithKline, Horizon, Inmedix, Janssen, Kiniksa, Lilly, Merck, MiMedx, Novartis, Omeros, Pfizer, R-Pharm, Regeneron, Samsung, Sandoz, Sanofi, Scipher, Setpoint, Sorrento, Spherix, and Urica.T Takeuchi: Grant/research support from AbbVie and Eisai; consulting fees from AbbVie, Astellas Pharma, Eli Lilly Japan, and Gilead Sciences; speaker/honoraria from AbbVie, Astellas Pharma, Eisai, Eli Lilly Japan, Gilead Sciences, and Pfizer Japan.J Aelion: Grant or research support: AbbVie, Acceleron, Acelyrin, Aclaris Therapeutics, Alpine Immune Sciences, Amgen, AstraZeneca, Biogen, BMS, Eli Lilly, Galapagos, GSK, Horizon, Janssen, Novartis, Selecta, UCB, Ventyx; consultancy for AbbVie, Amgen, BMS, Janssen, Novartis; speaker for AbbVie and Amgen. N Chávez: Speakers bureau for AbbVie, Janssen, and Pfizer; consultant of AbbVie, Janssen, and Pfizer; grant/research support from AbbVie, Galapagos, Gilead, Pfizer, and Sanofi. P Mannucci Walter: consulting fees from AbbVie; grant/research support from AbbVie, Bristol-Myers Squibb, Lilly, Genentech/Roche, GSK, Janssen, and UCB. Atul Singhal: No conflicts of interest to declare. J Swierkot: Speaker, research grants, and consulting fees from AbbVie, Amgen, Astra Zeneca, Celltrion, Eli Lilly, Novartis, Sandoz, Pfizer, Roche, BMS, UCB, MSD, Accord, and Janssen.N Khan, X Bu, Y Li, SK Penn, HS Camp: Employee of AbbVie and may hold stock or options.